Anti-TNF compounds

1. A method for treating a TNF disorder in a subject, comprising:

administering to a subject having a TNF disorder, wherein the TNF disorder is a skin disorder, a composition comprising an oligonucleotide comprising mUmGmGmGmAmGT*A*G*A*T*G*mAmGmGmUmAmC (SEQ ID NO. 16), wherein the oligonucleotide is 18 nucleotides in length, wherein m is a 2′O methyl, wherein * is a phosphorothioate modification, and wherein the composition is administered in an effective amount to treat the TNF disorder by reducing the expression of TNF in the subject.

2. A method for reducing TNF levels in vivo, comprising:

administering to a subject a composition comprising an oligonucleotide comprising mUmGmGmGmAmGT*A*G*A*T*G*mAmGmGmUmAmC (SEQ ID NO. 16), wherein the oligonucleotide is 18 nucleotides in length, wherein m is a 2′O methyl, wherein * is a phosphorothioate modification, and wherein the composition is administered in an effective amount to reduce TNF levels in vivo.

3. The method of claim 1 , wherein the composition further comprises a carrier.

4. The method of claim 3 , wherein the carrier is a lipid based carrier.

5. The method of claim 3 , wherein the carrier is a nanoparticle.

6. The method of claim 1 , wherein the oligonucleotide further comprises a molecular species at: the 3′ end of the oligonucleotide; the 5′ end of the oligonucleotide; or both the 3′ and 5′ ends of the oligonucleotide.

7. The method of claim 6 , wherein the molecular species is selected from the group consisting of a spacer, a lipid, a sterol, cholesterol, stearyl, C16 alkyl chain, bile acids, cholic acid, taurocholic acid, deoxycholate, oleyl litocholic acid, oleoyl cholenic acid, glycolipids, phospholipids, sphingolipids, isoprenoids, such as steroids, vitamins, such as vitamin E, saturated fatty acids, unsaturated fatty acids, fatty acid esters, such as triglycerides, pyrenes, porphyrines, Texaphyrine, adamantane, acridines, biotin, coumarin, fluorescein, rhodamine, Texas-Red, digoxygenin, dimethoxytrityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, cyanine dyes (e.g. Cy3 or Cy5), Hoechst 33258 dye, psoralen, and ibuprofen.

8. The method of claim 6 , wherein the molecular species is a selected from the group consisting of a lipophilic moiety; a folic acid radical; a steroid radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; or a vitamin K radical.

9. The method of claim 6 , wherein the molecular species is connected directly to the compound through a linkage selected from the group consisting of phosphodiester, phosphorothioate, methylphosphonate, and amide linkages.

10. The method of claim 6 , wherein the molecular species is connected indirectly to the compound through a linker.

11. The method of claim 10 , wherein the linker is a non-nucleotidic linker selected from the group consisting of abasic residues (dSpacer), oligoethyleneglycol, such as triethyleneglycol (spacer 9) or hexaethylenegylcol (spacer 18), and alkane-diol, such as butanediol.

12. The method of claim 1 , wherein the composition is administered with another therapeutic.

13. The method of claim 12 , wherein the another therapeutic is an anti-inflammatory agent.

14. The method of claim 1 , wherein the oligonucleotide is conjugated to a detectable label.

15. The method of claim 2 , wherein the composition further comprises a carrier.

16. The method of claim 15 , wherein the carrier is a lipid based carrier.

17. The method of claim 15 , wherein the carrier is a nanoparticle.

18. The method of claim 2 , wherein the oligonucleotide further comprises a molecular species at: the 3′ end of the oligonucleotide; the 5′ end of the oligonucleotide; or both the 3′ and 5′ ends of the oligonucleotide.

19. The method of claim 1 , wherein the TNF disorder is selected from the group consisting of psoriasis, psoriasis in combination with psoriatic arthritis, psoriatic arthritis, and chronic plaque psoriasis.